Literature DB >> 6698081

Unilateral retroperitoneal lymph node dissection in patients with non-seminomatous testicular tumor in clinical stage I.

S D Fosså, O Klepp, S Ous, H H Lien, A E Stenwig, T Abyholm, O Kaalhus.   

Abstract

19 of 53 patients (36%) with non-seminomatous testicular cancer, clinical stage I (CS I), had retroperitoneal lymph node metastases, pathological stage II (PS II), demonstrated by retroperitoneal lymph node dissection (RLND). RLND was done unilaterally in peroperatively tumor-free patients (PS I: 34 patients; PS II: 3 patients) and bilaterally if metastatic lymph nodes were found peroperatively. Patients with PS II received adjuvant cis-platinum containing combination chemotherapy. Postoperative tumor activity was observed in 3 patients (median observation time: 31 months). They were cured by salvage chemotherapy. 12-18 months after RLND no ejaculatory disturbances were observed in 28 of 36 unilaterally operated patients. After unilateral RLND, 7 patients fathered children. Unilateral RLND seems to be a sufficient diagnostic procedure in patients with non-seminomatous testicular cancer, CS I, who were found tumor-free during the operation. Fertility is preserved in the majority of the unilaterally operated patients.

Entities:  

Mesh:

Year:  1984        PMID: 6698081     DOI: 10.1159/000463504

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  3 in total

Review 1.  Retroperitoneal lymph node dissection: an update in testicular malignancies.

Authors:  K Yadav
Journal:  Clin Transl Oncol       Date:  2017-02-01       Impact factor: 3.405

2.  Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer.

Authors:  Joseph A Pettus; Brett S Carver; Timothy Masterson; Jason Stasi; Joel Sheinfeld
Journal:  Urology       Date:  2008-11-20       Impact factor: 2.649

3.  Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection.

Authors:  K D Jacobsen; S Ous; H Waehre; H Trasti; A E Stenwig; H H Lien; N Aass; S D Fosså
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.